A comprehensive view of Merck & Co. Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Merck’s Vaxneuvance pneumococcal 15-valent conjugate vaccine for children ages 6 weeks to 17 years old; vaccine administered in four-dose series, provides superior immune response against pneumococcal serotype 3, unique serotypes 22F, 33F

Merck reports experimental injectable pneumococcal vaccine V116 met primary immunogenicity objectives in Phase 1-2 study; vaccine targets 21 strains of Streptococcus pneumoniae that cause 85% of pneumonia cases in adults 65 years and over in US

FDA reviewing application for approval of Merck’s injectable immunotherapy Keytruda pembrolizumab to prevent returning lung cancer after surgery; FDA decision expected by late January 2023

HHS reports sales of Pfizer’s COVID-19 oral antiviral Paxlovid outpaced drugs from other firms; 162,000 Paxlovid courses used in US in past week compared to 20,000 courses of Merck and Ridgeback’s Lagevrio, 16,000 courses of AstraZeneca’s Evusheld

Merck invests €440M to expand membrane, filtration production in Cork, Ireland; company spending €290M to expand Carrigtwohill site's cast membrane production for gene therapies, virus sterilization, and €150M to build new facility, adding 370 jobs

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count